Krystal Biotech Inc (KRYS)
177.14
-1.27
(-0.71%)
USD |
NASDAQ |
Sep 27, 16:00
177.07
-0.07
(-0.04%)
After-Hours: 20:00
Krystal Biotech Cash from Investing (Quarterly): -19.35M for June 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | -19.35M |
March 31, 2024 | -25.98M |
December 31, 2023 | -10.16M |
September 30, 2023 | 105.19M |
June 30, 2023 | -15.96M |
March 31, 2023 | 3.563M |
December 31, 2022 | -5.208M |
September 30, 2022 | -14.74M |
June 30, 2022 | -38.22M |
March 31, 2022 | -55.91M |
December 31, 2021 | -126.54M |
September 30, 2021 | -37.17M |
June 30, 2021 | -62.32M |
March 31, 2021 | -0.747M |
December 31, 2020 | -6.217M |
Date | Value |
---|---|
September 30, 2020 | -2.697M |
June 30, 2020 | -0.962M |
March 31, 2020 | -1.305M |
December 31, 2019 | -0.591M |
September 30, 2019 | -0.682M |
June 30, 2019 | -1.236M |
March 31, 2019 | -2.482M |
December 31, 2018 | -3.767M |
September 30, 2018 | -2.755M |
June 30, 2018 | -3.801M |
March 31, 2018 | 0.00 |
December 31, 2017 | -0.159M |
September 30, 2017 | -0.012M |
June 30, 2017 | -0.032M |
March 31, 2017 | -0.007M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-126.54M
Minimum
Dec 2021
105.19M
Maximum
Sep 2023
-15.80M
Average
-8.188M
Median
Cash from Investing (Quarterly) Benchmarks
Bioventus Inc | -0.077M |
ADMA Biologics Inc | -2.365M |
Axsome Therapeutics Inc | -0.052M |
Sarepta Therapeutics Inc | -98.53M |
Janux Therapeutics Inc | -190.88M |
Cash from Investing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -4.168M |
Cash from Financing (Quarterly) | 10.64M |
Free Cash Flow | -22.76M |
Free Cash Flow Per Share (Quarterly) | -0.1788 |
Free Cash Flow to Equity (Quarterly) | -5.299M |
Free Cash Flow to Firm (Quarterly) | -5.299M |
Free Cash Flow Yield | -0.44% |